A fund backed by investment bank Leerink Partners raised $313 million for investments in the health information technology sector. Boston-based Leerink Transformation Partners said its first fund was significantly oversubscribed compared with the $250 million it initially sought to raise. Co-founder Todd Cozzens is a medical device industry veteran and former Sequoia Capital partner; Dr. Jared […]
Baxter (NYSE:BAX) shares gained today after analysts at Leerink Partners upgraded their view of the stock, citing its strong free cash flow and a string of “beat-‘n’raise” quarters from the Chicago-area healthcare giant. Leerink analysts Danielle Antalffy and Rebecca Wang boosted their rating on BAX shares from “market perform” to “outperform” and boosted the price target to […]
Insulet’s (NSDQ:PODD) drug-delivery business will be a long-term growth driver for the company by as much as 20% a year for the next few years, according to Leerink Partners analysts. Billerica, Mass.-based Insulet generates 86% of its revenue from its OmniPod insulin delivery device, according to Leerink. The OmniPod technology could be easily adapted to […]
UPDATED May 20, 2016, with more results out of Paris. St. Jude Medical (NYSE:STJ) announced it won CE Mark approval in the European Union for its PressureWire X Guidewire fractional flow reserve measurement system and is launching the product in Europe. The company announced the launch and clearance at the EuroPCR meeting in Paris this week. […]
Neovasc (NASDAQ:NVCN) reported 2nd quarter sales ahead of estimates, though down from 2014 and marked by growing losses, but rallied around the progress of its Tiara transcatheter mitral valve implant feasibility trial. The company’s 30-patient Tiara 1 trial has 2 study patients implanted, in addition to 5 patients implanted through compassionate use regulations. Of the 3 compassionate […]
Updated May 12, 2014, at 5:30 p.m. with confirmation from St. Jude Medical.
Wall Street analysts released their predictions for the major medical device industry trends of 2013, and the outlook isn’t much to celebrate.